Spinifex Therapeutics

Having acted as external counsel on commercial and IP matters for Spinifex Pharmaceuticals from 2008, through a number of capital raises (including its 2014 re-domestication to USA). We also acted as lead local counsel alongside Goodwin Proctor (US) in the acquisition by Novo Nordisk in 2015 for US$200 million upfront payment plus undisclosed clinical development and regulatory milestones.